Jennifer M. Rubatt

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence

Laura J. Havrilesky, Clark M. Whitehead, Jennifer M. Rubatt et al. · Gynecologic Oncology · 2008 · 233 citations

Medicine, Gynecology, Oncology +16

Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study

Jennifer M. Rubatt, Kathleen M. Darcy, Alan D. Hutson et al. · Gynecologic Oncology · 2009 · 95 citations

Medicine, Oncology, Pathology +17

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Jennifer M. Rubatt, Kathleen M. Darcy, Chunqiao Tian et al. · Gynecologic Oncology · 2012 · 41 citations · Full text

Medicine, Gynecology, Oncology +11

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines

Brittany A. Davidson, Jennifer M. Rubatt, David L. Corcoran et al. · Frontiers in Oncology · 2014 · 40 citations · Full text

Medicine, Cancer Biology, Oncology +17

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells

Deanna Teoh, Tina A. Ayeni, Jennifer M. Rubatt et al. · Gynecologic Oncology · 2011 · 39 citations

Medicine, Oncology, Pharmacology +11